Revenue Showdown: United Therapeutics Corporation vs Taro Pharmaceutical Industries Ltd.

Pharma Giants' Revenue Battle: United Therapeutics vs. Taro

__timestampTaro Pharmaceutical Industries Ltd.United Therapeutics Corporation
Wednesday, January 1, 20147592850001288519000
Thursday, January 1, 20158629440001465761000
Friday, January 1, 20169507510001598800000
Sunday, January 1, 20178793870001725300000
Monday, January 1, 20186619130001627800000
Tuesday, January 1, 20196698930001448800000
Wednesday, January 1, 20206447690001483300000
Friday, January 1, 20215489700001685500000
Saturday, January 1, 20225613470001936300000
Sunday, January 1, 20235729520002327500000
Monday, January 1, 2024629182000
Loading chart...

Unleashing insights

Revenue Showdown: A Tale of Two Pharmaceutical Giants

In the competitive landscape of pharmaceuticals, United Therapeutics Corporation and Taro Pharmaceutical Industries Ltd. have been key players. From 2014 to 2023, United Therapeutics consistently outperformed Taro, with revenues peaking at approximately $2.3 billion in 2023, marking an impressive 80% increase from 2014. In contrast, Taro's revenue saw a decline, dropping by about 24% over the same period, from $759 million in 2014 to $573 million in 2023. This divergence highlights United Therapeutics' robust growth strategy and market adaptability, while Taro faced challenges in maintaining its revenue stream. The data for 2024 is incomplete, but the trends suggest a continued trajectory for United Therapeutics, while Taro may need strategic shifts to regain its footing. This revenue showdown underscores the dynamic nature of the pharmaceutical industry and the importance of innovation and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025